<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The desired outcome of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>Accordingly, immunological assays that demonstrate recognition of native <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells (<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific) may be more clinically relevant than assays that demonstrate recognition of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> protein or <z:chebi fb="7" ids="16670">peptide</z:chebi> (antigen-specific) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Towards this goal, we adapted the IFN-gamma ELISPOT assay to measure immune responses against autologous <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> cells in vaccinated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>As a model system to develop the assay, we utilized peripheral blood mononuclear cells (PBMC) directly isolated from follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients vaccinated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-derived idiotype protein </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: After optimizing several variables, we demonstrated that the modified IFN-gamma ELISPOT assay could be used to reliably and reproducibly determine the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-reactive T cell frequency in the PBMC of these patients </plain></SENT>
<SENT sid="5" pm="."><plain>The precursor frequency of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-reactive T cells was significantly higher in the postvaccine PBMC, compared with prevaccine samples in <z:hpo ids='HP_0000001'>all</z:hpo> patients tested </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, the specificity of these T cells was established by the lack of reactivity against autologous <z:mpath ids='MPATH_458'>normal</z:mpath> B cells </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: These results demonstrate the feasibility of quantitating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific T cell responses when autologous, <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> cells are available as targets </plain></SENT>
</text></document>